Dr. Gang Qin, Ph.D. (University of Göttingen), is the Founder and CEO of GeneQuantum Healthcare. With over 20 years of international experience in biopharmaceutical R&D and leadership—spanning roles at the Max Planck Institute and the Chinese Academy of Sciences—Dr. Qin is a recognized innovator in the field, credited with numerous high-impact scientific publications and over 180 patent applications as a core inventor. At GeneQuantum, Dr. Qin leads the company’s mission to revolutionize targeted cancer therapies through its proprietary, enzyme-mediated site-specific conjugation technologies. Under his leadership, GeneQuantum has established a fully integrated, high-throughput platform for the discovery and manufacturing of next-generation XDC therapeutics. This end-to-end solution supports the efficient development of best-in-class and first-in-class (BIC/FIC) XDC candidates, targeting oncology and other indications with substantial unmet medical needs and high market potential.